We’re raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat

Leave a Comment / By Market Social / February 5, 2026

Combined sales for the company’s blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.

Post navigation

Builders pitch ‘Trump home’ policies, stoking gains for their stocks

Anthropic takes aim at OpenAI’s ad push in Super Bowl commercial

Your email address will not be published. Required fields are marked *

Comment *

Name*

Email*

Website

Save my name, email, and website in this browser for the next time I comment.

Markets

Trading

About Us

Name * Only alphabets are allowed.

Password

Again Password

Referral (Optional)

Support Language

Whatsapp Number *

OTP